Yonan C[au] - Search Results

Year	Number of Results
1991	4
1994	1
2000	2
2005	1
2008	1
2011	1
2014	1
2015	4
2016	5
2017	2
2018	3
2019	2
2020	1
2021	5
2022	1

1

Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.

Ganz ML, Chavan A, Dhanda R, Serbin M, Yonan C. Ganz ML, et al. Among authors: yonan c. J Med Econ. 2021 Jan-Dec;24(1):103-113. doi: 10.1080/13696998.2020.1867443. J Med Econ. 2021. PMID: 33393412 Free article. Updated.

2

Patient perspective of tardive dyskinesia: results from a social media listening study.

Farrar M, Lundt L, Franey E, Yonan C. Farrar M, et al. Among authors: yonan c. BMC Psychiatry. 2021 Feb 15;21(1):94. doi: 10.1186/s12888-021-03074-9. BMC Psychiatry. 2021. PMID: 33588795 Free PMC article.

3

Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study.

Cutler AJ, Caroff SN, Tanner CM, Shalhoub H, Lenderking WR, Pagé V, Franey E, Yonan C. Cutler AJ, et al. Among authors: yonan c. J Am Psychiatr Nurses Assoc. 2021 Jun 22:10783903211023565. doi: 10.1177/10783903211023565. Online ahead of print. J Am Psychiatr Nurses Assoc. 2021. PMID: 34154444 Free article.

4

Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.

Hansen RN, Suh K, Serbin M, Yonan C, Sullivan SD. Hansen RN, et al. Among authors: yonan c. J Med Econ. 2021 Jan-Dec;24(1):563-569. doi: 10.1080/13696998.2021.1916750. J Med Econ. 2021. PMID: 33866942 Free article.

5

In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113.

Serbin M, Yonan C, Ganz ML. Serbin M, et al. Among authors: yonan c. J Med Econ. 2021 Jan-Dec;24(1):891-892. doi: 10.1080/13696998.2021.1948233. J Med Econ. 2021. PMID: 34166165 Free article. No abstract available.

6

Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.

Caroff SN, Aggarwal S, Yonan C. Caroff SN, et al. Among authors: yonan c. J Comp Eff Res. 2018 Feb;7(2):135-148. doi: 10.2217/cer-2017-0065. Epub 2017 Oct 2. J Comp Eff Res. 2018. PMID: 28965423 Free article.

7

The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.

McIntyre RS, Calabrese JR, Nierenberg AA, Farahmand K, Yonan C, Siegert S, Burke J. McIntyre RS, et al. Among authors: yonan c. J Affect Disord. 2019 Mar 1;246:217-223. doi: 10.1016/j.jad.2018.12.023. Epub 2018 Dec 17. J Affect Disord. 2019. PMID: 30583148 Free article. Clinical Trial.

8

Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.

Aggarwal S, Serbin M, Yonan C. Aggarwal S, et al. Among authors: yonan c. J Comp Eff Res. 2019 Oct;8(13):1077-1088. doi: 10.2217/cer-2019-0059. Epub 2019 Aug 29. J Comp Eff Res. 2019. PMID: 31464152 Free article.

9

RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.

Caroff SN, Yeomans K, Lenderking WR, Cutler AJ, Tanner CM, Shalhoub H, Pagé V, Chen J, Franey E, Yonan C. Caroff SN, et al. Among authors: yonan c. J Clin Psychopharmacol. 2020 May/Jun;40(3):259-268. doi: 10.1097/JCP.0000000000001201. J Clin Psychopharmacol. 2020. PMID: 32332461 Free PMC article.

10

Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool.

Allen C, Zarowitz B, O'Shea T, Peterson E, Yonan C, Waterman F. Allen C, et al. Among authors: yonan c. Geriatr Nurs. 2018 Jan-Feb;39(1):54-59. doi: 10.1016/j.gerinurse.2017.06.002. Epub 2017 Aug 12. Geriatr Nurs. 2018. PMID: 28807457

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results